52
views
0
recommends
+1 Recommend
0 collections
    7
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.

      1 , 2 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 4 , 5 , 6 , 7 , 3 , 8 , 9 , 10 , 11 , 12 , 13 , 13 , 14 , 15 , 16 , 17 , 18 , 18 , 19 , 5 , 20 , 21 , 21 , 22
      Cell host & microbe

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The third variable (V3) loop and the CD4 binding site (CD4bs) of the HIV-1 envelope are frequently targeted by neutralizing antibodies (nAbs) in infected individuals. In chronic infection, HIV-1 escape mutants repopulate the plasma, and V3 and CD4bs nAbs emerge that can neutralize heterologous tier 1 easy-to-neutralize but not tier 2 difficult-to-neutralize HIV-1 isolates. However, neutralization sensitivity of autologous plasma viruses to this type of nAb response has not been studied. We describe the development and evolution in vivo of antibodies distinguished by their target specificity for V3 and CD4bs epitopes on autologous tier 2 viruses but not on heterologous tier 2 viruses. A surprisingly high fraction of autologous circulating viruses was sensitive to these antibodies. These findings demonstrate a role for V3 and CD4bs antibodies in constraining the native envelope trimer in vivo to a neutralization-resistant phenotype, explaining why HIV-1 transmission generally occurs by tier 2 neutralization-resistant viruses.

          Related collections

          Author and article information

          Journal
          Cell Host Microbe
          Cell host & microbe
          1934-6069
          1931-3128
          Sep 9 2015
          : 18
          : 3
          Affiliations
          [1 ] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA; Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: moody007@mc.duke.edu.
          [2 ] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: feng.gao@dm.duke.edu.
          [3 ] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
          [4 ] Centre de Recherche du CHUM and Department of Microbiology, Infectology and Immunology, Université de Montréal, Montreal, QC H2X 0A9, Canada and Department of Microbiology and Immunology, McGill University, Montreal, QC H2X 1P1, Canada.
          [5 ] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
          [6 ] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA; Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
          [7 ] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
          [8 ] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA; Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
          [9 ] University of North Carolina Project, Kamuzu Central Hospital, Lilongwe, Malawi.
          [10 ] Departments of Medicine, Epidemiology, Microbiology, and Immunology, University of North Carolina, Chapel Hill, NC 27599, USA.
          [11 ] Kilimanjaro Christian Medical Center, Moshi 25102, Tanzania.
          [12 ] London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.
          [13 ] National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
          [14 ] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
          [15 ] Department of Pathology, New York University School of Medicine, New York, NY 10010, USA; Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA.
          [16 ] Department of Pathology, New York University School of Medicine, New York, NY 10010, USA.
          [17 ] Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
          [18 ] Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
          [19 ] Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
          [20 ] Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
          [21 ] Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
          [22 ] Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA; Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA; Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: hayne002@mc.duke.edu.
          Article
          S1931-3128(15)00334-0 NIHMS719010
          10.1016/j.chom.2015.08.006
          4567706
          26355218
          f653a0cd-ba85-4d21-b61d-a46a6fa78b57
          Copyright © 2015 Elsevier Inc. All rights reserved.
          History

          Comments

          Comment on this article